Beacon Therapeutics
PrivateLast Round
Series C
Jan 8, 2026
Est. Valuation
$618.75M
Total Funding Raised
$365M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Beacon Therapeutics operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Series C round in January 2026.
Beacon Therapeutics is a biotechnology company that develops adeno-associated virus gene therapies to treat patients with rare and prevalent retinal diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Beacon Therapeutics Comparables
Compare Beacon Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neurophth | 86% | |
| 4DMT | 86% | |
| MeiraGTx Holdings | 85% |
For institutional investors. Book with your work email.
Beacon Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jan 8, 2026 | ||||
| Series B | Jul 3, 2024 | ||||
| Series A | Jun 12, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Beacon Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series B |
| TCG Crossover | Series B |
| Forbion | Series C, Series B |
| Syncona | Series B, Series C, Series A |
| Oxford Science Enterprises | Series A, Series B, Series C |
| Life Sciences at Goldman Sachs Alternatives | Series C |
| Advent Life Sciences | Series B, Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 8, 2026
$75M round raised at $618.75M post-money valuation.
- Jan 8, 2026
Colin Walsh, Managing Director at Goldman Sachs Alternatives, joins the board.
For institutional investors. Book with your work email.
Beacon Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Beacon Therapeutics's valuation, stock price, and market status.
Is Beacon Therapeutics a public or private company?
Beacon Therapeutics is a private company.
What is the current stock price of Beacon Therapeutics?
Beacon Therapeutics is a private company, so its shares have no public market price. Caplight tracks Beacon Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Beacon Therapeutics worth (valuation)?
Beacon Therapeutics's valuation is estimated at $618.8M based on funding round data.
Can I buy Beacon Therapeutics stock?
Beacon Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Beacon Therapeutics's last funding round?
Beacon Therapeutics's most recent funding round was Series C on January 8, 2026.
Who are the main investors in Beacon Therapeutics?
Key investors in Beacon Therapeutics include Forbion Capital Partners, Forbion, Syncona, Life Sciences at Goldman Sachs Alternatives, Goldman Sachs Alternatives.
Will Beacon Therapeutics IPO soon?
No public IPO plans have been announced for Beacon Therapeutics.
How can I track Beacon Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Beacon Therapeutics's shares on secondary markets.